Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actinonin is a naturally occurring hydroxamic acid antibiotic originally isolated from Streptomyces species. It is a small molecule inhibitor of peptide deformylase, an enzyme involved in the removal of formyl groups from nascent proteins during bacterial protein synthesis. By inhibiting this enzyme, actinonin disrupts bacterial growth and has been studied for its antibacterial properties. Additionally, it has been investigated as an experimental tool compound in research on metalloproteases and related enzymes[1][2]. Its primary use remains experimental; it is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on actinonin.